wellCorner
WELLCORNER, LLC LAUNCHES NEW HEALTH & WELLNESS PRODUCT LINES FOR CANCER PATIENTS AT ITS NURSE SYMPOSIUM ON JUNE 15, 2022
August 30, 2022 07:00 ET | wellCORNER, LLC
NEW HOPE, Pa., Aug. 30, 2022 (GLOBE NEWSWIRE) -- wellCORNER, LLC an innovative company committed to providing education and access to natural, high-quality complementary products for cancer patients...
NOVARTIS logo.jpg
Novartis presents new data in breast and prostate cancer at ESMO
August 30, 2022 01:15 ET | Novartis Pharma AG
Overall survival results from pooled exploratory analysis of MONALEESA trials in patients with aggressive HR+/HER2- advanced breast cancer treated with Kisqali® Data from VISION study reporting...
logo_tau.png
Alpha Tau Medical Announces Second Quarter 2022 Financial Results and Provides Corporate Update
August 25, 2022 16:05 ET | Alpha Tau Medical Ltd.
-Received FDA Conditional Investigational Device Exemption (IDE), whose conditions have since been satisfied, to initiate a pivotal trial of Alpha DaRT™ in recurrent cutaneous squamous cell carcinoma....
SERMONIX NEW LOGO JPEG (2).jpg
Sermonix Pharmaceuticals Announces Top-Line Data From ELAINE 1 Phase 2 Study of Lasofoxifene Versus Fulvestrant Is Accepted for a Late-Breaking Oral Presentation at ESMO Congress 2022
August 25, 2022 09:00 ET | Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated...
Elevar Logo for Common Use.png
Elevar Therapeutics Announces Data From Phase 3 Study of Rivoceranib in Combination With Camrelizumab Is Accepted for Late-Breaking Proffered Paper Presentation at ESMO Congress 2022
August 25, 2022 07:00 ET | Elevar Therapeutics
SALT LAKE CITY, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who...
PDS Biotech Logo.png
PDS Biotech Completes $35 Million Financing Agreement Led By Horizon Technology Finance
August 24, 2022 16:01 ET | PDS Biotechnology Corporation
Initial tranche of $25 million provides funding in preparation for registrational trial for lead candidate PDS0101Conference call scheduled for Thursday, August 25, 2022 at 8:00 AM EDT FLORHAM PARK,...
Straits Research Pvt Ltd
Pharmacogenomics Market Size is projected to reach USD 11.79 Billion by 2030, growing at a CAGR of 8.47%: Straits Research
August 23, 2022 15:35 ET | Straits Research
New York, USA, Aug. 23, 2022 (GLOBE NEWSWIRE) -- The global pharmacogenomics market is expected to grow due to the constantly rising need for treating fatal diseases like cancer and increasing...
New Leaders Appointed to FCS Senior Management Team
Florida Cancer Specialists & Research Institute Appoints New Members to Senior Management
August 22, 2022 13:30 ET | Florida Cancer Specialists & Research Institute
Fort Myers, Fla., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Florida Cancer Specialists & Research Institute, LLC (FCS) is pleased to welcome the following members to its senior management team. Jon...
logo_tau.png
Alpha Tau and MIM Software Announce Collaboration for Alpha DaRT Treatment Planning
August 22, 2022 09:00 ET | Alpha Tau Medical Ltd.
JERUSALEM and CLEVELAND, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Today, Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, and...
POINT-Logo-Colour (blue).png
POINT Biopharma to Publish Abstract at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial
August 18, 2022 16:30 ET | POINT Biopharma
In advance of the abstract publication, POINT hosted an educational webinar entitled “Understanding the PNT2002 Phase 3 SPLASH Trial Control Arm” Watch the replay at...